<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-504
Date of Submission: 2025-02-10

This report was submitted by a Other Healthcare Professional from Morales Inc Medical Center concerning patient ANON-PX-2307. The subject is a 87-year-old female with a significant medical history including type 2 diabetes, hypertension. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. 

Current medication review revealed the following suspected agent(s): Ibuprofen administered via the Intramuscular route at a dosage of 361mg, initiated on 2025-01-10 for Pain and inflammation and discontinued on 2025-02-07.

On approximately 2025-02-06, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Headache, Maculopapular Rash, Pruritus, Anaphylaxis. The Headache was classified as Moderate in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Fatal'. The Maculopapular Rash was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'. The Pruritus was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'. The Anaphylaxis was classified as Moderate in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Unknown'. 

CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 5 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Not applicable'. The on-site pharmacist concurred with the assessment during a routine case review. 

Reporter's Narrative Summary: Son new line sea technology. Grow nothing trial weight including.</data>
report_id: ADR-2025-504
report_date: '2025-02-10'
patient_details:
  patient_id: ANON-PX-2307
  gender: Female
  relevant_history:
  - type 2 diabetes
  - hypertension
  age_at_reaction: 87
suspected_drugs:
- drug_name: Ibuprofen
  dosage: 361mg
  route_of_administration: Intramuscular
  start_date: '2025-01-10'
  indication_for_use: Pain and inflammation
  end_date: '2025-02-07'
adverse_reactions:
- symptom_name: Headache
  onset_date: '2025-02-06'
  severity: Moderate
  outcome: Fatal
  intervention_required: true
- symptom_name: Maculopapular Rash
  onset_date: '2025-02-06'
  severity: Life-threatening
  outcome: Recovered
  intervention_required: false
- symptom_name: Pruritus
  onset_date: '2025-02-06'
  severity: Severe
  outcome: Not Recovered
  intervention_required: false
- symptom_name: Anaphylaxis
  onset_date: '2025-02-06'
  severity: Moderate
  outcome: Unknown
  intervention_required: true
causality_assessment:
  assessment_conclusion: Probable
  dechallenge_rechallenge: Not applicable
  naranjo_score: 5
reporting_facility: Morales Inc Medical Center
reporter_type: Other Healthcare Professional
notes: Son new line sea technology. Grow nothing trial weight including.
